RxDoctor Payments Data

Sarah Laibstain, MD

Family Medicine · Dallas, TXNPI 1598994337

Payments from drug & device makers

$671in general payments, 2019–2025

Across 44 payments — averaging $15.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$152
  • AbbVie$101
  • GSK$76
  • Exact Sciences$59
  • Pfizer$47
  • Teva Pharmaceuticals USA, Inc.$42
  • plus $195 from 11 others

What the payments were for

  • Food & beverage$671100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$671 in reported general payments places this provider in the 55th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$13,025
Medicare patients
59
Services billed
186

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide108$203,596
EliquisApixaban34$49,901
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$44,738
RybelsusSemaglutide19$40,804
FarxigaDapagliflozin Propanediol32$36,225
XareltoRivaroxaban19$33,165
JardianceEmpagliflozin25$30,214
MyrbetriqMirabegron20$26,934
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr31$20,021
JanuviaSitagliptin Phosphate12$17,620
LinzessLinaclotide11$16,905
Albuterol Sulfate HfaAlbuterol Sulfate150$7,645
Atrovent HfaIpratropium Bromide15$6,262
Tresiba Flextouch U-100Insulin Degludec15$6,165
Lantus SolostarInsulin Glargine,hum.Rec.Anlog34$4,833

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$15$244,400127 claims
GSKTrelegy Ellipta, Anoro Ellipta$76$64,75956 claims
PfizerEliquis$47$49,90134 claims
AstraZenecaFarxiga$152$36,22532 claims
MerckJanuvia$11$17,62012 claims
AbbVieLinzess$101$16,90511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →